Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma

IntroductionAnaplastic lymphoma kinase (ALK) fusion mutation is more common in younger and never-smoking lung cancer patients. The association of smoking and ALK-tyrosine kinase inhibitors (TKIs) on overall survival (OS) of treatment-naïve ALK-positive advanced lung adenocarcinoma remains unclear in...

Полное описание

Библиографические подробности

Главные авторы:	Zhe-Rong Zheng, Hsiu-Ying Ku, Kun-Chieh Chen, Chun-Ju Chiang, Chih-Liang Wang, Chih-Yi Chen, Chun-Ming Tsai, Ming-Shyan Huang, Chong-Jen Yu, Jin-Shing Chen, Teh-Ying Chou, Wen-Chung Lee, Chun-Chieh Wang, Tsang-Wu Liu, Jiun-Yi Hsia, Gee-Chen Chang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2023-03-01
Серии:	Frontiers in Oncology
Предметы:	lung cancer TKI - tyrosine kinase inhibitor smoking ALK (anaplastic lymphoma kinase) non-small cell lung cancer ALK non-small cell lung cancer
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1063695/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!